This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been
BMS’ checkpoint inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients.
Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the treatment showed an ability to improve survival compared to Sutent.
BMS’ PD-L1 inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients. ... Armed with two Opdivo combinations in its arsenal, BMS is primed to take on
inhibitor Yervoy (Ipilimumab).
Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the treatment showed an ability to improve survival compared to Sutent.
More from news
Approximately 8 fully matching, plus 176 partially matching documents found.
Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better long-term survival than the Keytruda/chemotherapy combination which is driving the growth
This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.
drug Yervoy (ipilimumab) in an early-stage trial.
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is FDA approved for late-stage melanoma.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
drug Yervoy (ipilimumab).
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary
In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...